Study summary · research use only
Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review analyzes the patent landscape for mazdutide, a dual GLP-1 receptor and glucagon receptor agonist, and related oxyntomodulin analogs. Using the Patentscope database, the authors examined patent filings from 2015 to 2025 and analyzed twelve patent families covering composition-of-matter, process chemistry, formulation technologies, dosing regimens, and therapeutic applications. The review traces development from Eli Lilly's early peptide design through Innovent Biologics' later formulation, clinical, and indication-expansion work covering obesity, type 2 diabetes, hyperuricemia, and adolescent obesity, and describes layered patent strategies spanning molecular design, manufacturability, formulation stability, and clinical-use claims.
Abstract
Mazdutide is a dual glucagon-like peptide-1 receptor (GLP-1 R) and glucagon receptor (GCGR) agonist representing a new generation of incretin-based therapeutics for obesity and type 2 diabetes. While its clinical efficacy is increasingly recognized, the intellectual property framework that underpins its development and long-term positioning has not been systematically examined. This review presents a comprehensive patent landscape analysis of mazdutide and related oxyntomodulin analogs. Patent documents were identified using the Patentscope database, covering filings between 2015 and 2025. Twelve patent families were analyzed, encompassing composition-of-matter, process chemistry, formulation technologies, dosing regimens, and therapeutic applications. The analysis traces the evolution of innovation from early peptide design by Eli Lilly to later formulation, clinical, and indication-expansion strategies led by Innovent Biologics, including obesity, type 2 diabetes, hyperuricemia, and adolescent obesity. Mazdutide illustrates how layered patent strategies integrating molecular design, manufacturability, formulation stability, and clinical use claims can secure durable exclusivity. This approach provides a strategic model for future dual and multi-receptor peptide therapeutics.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.